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serum multimeric gelatinolytic activity; (2) a cytoplasmatic 
reactivity in meningiomas with a significantly increase 
in atypical meningioma compared with low-grade ones 
(p = 0.036); (3) a positive correlation between MMP-9 and 
Ki-67 (Sperman Rho coefficient r = 0.418 and p = 0.034). 
Our results suggest that serum and tissue MMP-9 might 
provide clinicians additional objective information in intra-
cranial neoplasms. Finally, it should be possible to use 
MMP-9 as a target for new forms of therapy. Neverthe-
less, due to the small number of patients included in the 
study, the conclusion may not be transferable to the general 
population and therefore further evaluations are needed.
Keywords Matrix metalloproteinases · Se um · 
Tumors · Central nervous system
Introduction
Tumors of the central nervous system (CNS) represent one 
of the most common causes of cancer death and account 
for about 1.3 % of all malignant cancer, with an incidence 
of 7 per 100,000 persons worldwide [1, 2]. CNS tumors 
onsi t of a heterogeneous group of neoplasms, including 
different variant of primary brain tumors (glial or non-
glial, benign or malignant) and metastatic neoplasms [3, 
4]. Metastatic brain tumors include malignant tumors that 
arise elsewhere in the body (such as the breast or lungs) and 
migrate to the brain, usually through the bloodstream. The 
number of primary and metastatic brain tumors is steadily 
climbing, whereas mortality rate for most tumor types have 
remained essentially unchanged. In particular, patients with 
high grade glioma usually have the worst prognosis with a 
median survival of 12 months even after surgical resection, 
radiation therapy and chemotherapy [5].
Abstract The basement membrane collagen IV-degrad-
ing matrix metalloproteinases -2 a d -9 (MMPs) are most 
often linked to the maligna t phenotype of tum r cells by 
playing a critical role in invasion, metastasis, angiogenesis, 
and vasculogenesis. We verified the activity of these two 
MMPs in the sera of patients affected by brain tumors (20 
gliomas, 28 meningiomas and 20 metastasis) by zymogra-
phy. The sera of 25 healthy volu teers with no concomitant 
illnesses were used for control . Zymography showed four
dominant gelatinolytic bands of 240, 130, 92 (MMP-9) nd
72 (MMP-2) kDa. No statistically significant variations of 
MMP-2 proteolytic activity between patie ts and healthy 
individuals were observed. On the contrary, MMP-9 (both 
monomeric and multimeric forms) lytic activiti s w re ig-
nificantly higher in tumors specimens compared to healthy 
controls (p < 0.001). Moreover, MMP-9 immunohistochem-
istry revealed: (1) a strong reactivity in neoplastic vessels 
of high-grade gliomas showing an inverse correlation with 
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angiogenesis and vasculogenesis in late steps of tumor 
growth [13]. High expression of MMP-2 and MMP-9 has 
been often associated to malignant phenotype of many 
tumor types, with positive correlation with tumor grading 
and/or staging [14], thus, they obtained a deep interest as 
new potential biomarkers.
In the present study, we determined MMP-2 and MMP-9 
activity in sera from patients with intracranial carcinoma, by 
using gelatin zymography, in order to analyze the pattern of 
gelatinolytic activity and to verify whether they may have 
potential as non-invasive biomarkers in providing useful 
clinical information.
Materials and methods
Study design
This was a unicentre observational study. All patients 
affected by intracranial neoplasms treated at the Neurosur-
gery Unit of the University of Naples “Federico II” in one 
year were potentially eligible. Patients were excluded if (1) 
they had other concomitant illnesses; (2) they had evidence 
of recent intracranial hemorrhage; (3) they had history 
of intracranial abscess; (4) they did not have a definitive 
diagnosis at the end of diagnostic work-up. MMP-2 and -9 
were evaluated in serum by substrate gelatin zymography; 
MMP-9 tissue expression was evaluated by immunohisto-
chemistry in surgical specimens of glioma and meningi-
oma, not in metastases. In all meningiomas also Ki-67 and 
progesterone receptor (PR) stainings were performed. The 
protocol of this study was approved by the Hospital Ethics 
Committee of the University of Naples “Federico II” and 
written informed consent was obtained from all individuals 
before being included in the study.
Patient population
A total of 68 patients with intracranial tumors were evalu-
ated. Diagnosis of tumors was made by usual clinical criteria 
and confirmed post-operatively by histopathological find-
ings according to the latest WHO classification of tumors 
of the central nervous system [3,4]. The age of patients was 
between 17 and 87 years with a median age of 64 ± 15.2 and 
there were 37 males and 31 females. The study included 20 
gliomas, 28 meningiomas and 20 metastases. The clinical-
pathological characteristics are listed in Tables 1, 2 and 3. 
Twenty-five healthy volunteers with no concomitant ill-
nesses were used as controls. The age of healthy volunteers 
was between 47 and 85 years (62 ± 10.3) and there were 11 
males and 14 females. Healthy volunteers gave their per-
mission verbally. The subjects in the controls had no sign 
of infections, gastrointestinal, hepatic or renal disease, nor 
Actually, the main diagnostic tools for both primary and 
metastatic CNS tumors are the anamnestic n urological 
examination, the imaging tests, such as conventional g-
netic resonance (MRI) and comp te ized tomogra hy (CT) 
scan [2]. Advanced imaging techniques improve the neuro-
radiological diagnostic accuracy; however, they xpensive 
and lack of specificity, thus there is a pressing need of 
non-invasive methods to di gnose carcinom  of the CNS 
as well as for their management. Currently, except for ra e 
germ cell tumors, there is no me hod to prospectively detect 
brain tumor until they have progressed to sympt stag . Thus, 
detection, definition and validation of new biomarkers for 
diagnosis, prognosis, disease monitoring, as well as thera-
peutic efficacy and tumor progression, are recognized as 
formidable challenges in oncolog c research.
For long time basic cancer research has mainly focused 
on mutations in cancer cells that result in either gain or loss 
some functions of cells. However, more recent evidences 
characterize cancer development as the result of disrupted 
intra- and inter-cellular homeostatic regulation. Onc  the 
homeostatic balance has been lost and malignant transfor-
mation has occurred, micro-environmental process s, such 
as degradation of matrix components and host-tumor inter-
actions, promote survival and grow h of malignant cells 
[6]. Therefore, proteins and e zymes involved in d grada-
tion of extra-cellular matrix (ECM) have been shown to be 
essential for cancer progression, by prov ding tumor cells 
with access to vascular and lymphatic systems which sup-
port tumor growth and represent an escape oute for further 
dissemination. Among all proteoly ic enzymes potentially 
associated with tumor invasion, m mbers of the matrix 
metallo-proteinases (MMPs) family are prime candidate , 
due to their ability to collectively degrade all components of 
the ECM and basement membranes [7–11]. In particular, the 
ability to degrade type IV collag n (gelatin), the major com-
ponent of the ECM and basement membranes, is unique to 
gelatinase A (MMP-2) and gelatinas  B (MMP-9) [9]. Both 
MMP-2 and MMP-9 are expressed in fibroblasts, leuko-
cytes, macrophages and endothelial cells, and are involved 
in the mechanical removal of structural pro eins in the 
extracellular matrix, but als  in th  regulati n of multiple 
cellular functions includi g ell growth, poptosi , angio-
genesis and immune response, by cl aving growth factor-
precursors, cell adhesion molecules, cell surface receptors 
and other bioactive proteins [12]. Nowadays,  is widely 
recognized that gelatinases participate to the aetiology of a 
plethora of normal biologic l and non-tumoral pathologic l 
processes, such as autoimmune diseases, cardiometabolic 
diseases, neurological disorders, breakdown of blood-brain-
barrier, skin ulceration etc. [13]. Th y are also important in 
the formation of the complex microenvironment which (1) 
promotes malignant transformat in e r  st p  of tumor 
evolution, (2) stimulates cell proliferation and modulate 
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Systems Inc. (Tucson, AZ, USA); and MMP-2, MMP-9 anti-
bodies from Sigma Chemical Co. (St. Louis, MO, USA). All 
other reagents were available from commercial sources.
Gelatin zymography
Gelatinolytic activity was performed as previously 
described [16]. Briefly, total protein (25 µg) of each sample 
was mixed with sample buffer (10 mM Tris–HCl pH 6.8, 
12.5 % SDS, 5% sucrose, 0.1 % bromophenol blue) and 
applied directly without prior heating or reduction to 7.5 % 
(w/v) acrylamide gels containing 0.3 % (w/v) of gelatin  
After removal of SDS from the gel by incubation in 2.5% 
(v/v) Triton X-100 for 1 h, the gels were incubated at 37 °C 
for 18 h in 50 mM Tris–HCl pH 7.6 containing 0.2 M NaCl, 
5 mM CaCl2, and 0.02 % (w/v) Brij 35. Gels were stained 
for 1 h in 30 % methanol, 10 % glacial acetic acid containing 
0.5 % (w/v) Coomassie Brilliant Blue G 250 and destained 
in the same solution without dye for several hours. The 
gelatinolytic activity of each collagenase was evident as a 
clear band against the blue background of stained gelatin. 
The molecular size of bands displaying enzymatic activity 
were identified by comparison with prestained standard pro-
tein, as well as with purified gelatinase A or B. To normal-
ize the possible difference between zymograms an internal 
serum sample from a patient was incorporated in every gel. 
tumors or immunological diseas . The val e  of basic labo-
ratory parameters of these participants were within the ref-
erences limits.
Serum samples
Peripheral venous blood samples were collected preop-
eratively. Native serum was prepar using plastic tubes 
without coagulation acceler tors, to prevent the rel ase of 
gelatinases during platelet activation. Tubes were centri-
fuged at 1600 g for 10 min, 30 min after blood collection. 
For each sample, determination of prote n concentra io  
was performed using the method of Bradford [15]. S ra 
were aliquoted and stored at −20 °C until used. Each aliquot 
was used only once in order to prevent enzyme activat on
due to freeze-thawing processes.
Materials
Gelatinase A and gelatinase B were purchased from Hof-
mann-La Roche Ltd (Basel, Switz rland). C lc um chlo-
ride (CaCl2) g ycerol, gelatin, ethylen diaminetetraacetic 
(EDTA), Triton X-100, phenylmethylsulphonyl fluride 
(PMSF) were from Sigma Chemical Co. (St. Louis, MO,
USA). Ki-67 antibody (MIB1) from Dako (Milano, Italy); 
progesterone receptor antibody (1E2) from Ventana Medical 
Table 3 Serum MMP-2 and MMP-9 levels in brain metastasis patients
CaseSexAgeDiagnosisLocalizationSerum MMPs (vol × 10−3)
MMP-9 (240 kDa)MMP-9 (130 kDa)MMP-9 (92 kDa)MMP-2 (72 kDa)
49 M 64 MelanomaLeft temporal lobe212 nd 1233 755
50 M 61 MelanomaRight frontal lobe160 67 1426 703
51 M 66 MelanomaCerebellum208 104 1717 330
52 M 50 MelanomaFrontal lobe100 45 940 384
53 F 58 MelanomaEncephalon, NOS198 318 1183 540
54 F 52 MelanomaLeft frontal lobe145 111 1450 1228
55 M 32 MelanomaParietal lobe149 233 1194 334
56 M 77 MelanomaEncephalon, NOS306 719 2040 1132
57 M 67 MelanomaRight temporal lobe305 217 1531 470
58 M 80 MelanomaRight occipital lobe89 nd 556 353
59 F 87 NSCLC Right cerebellum254 nd 1202 518
60 M 57 NSCLC Left occipital lobe361 195 1672 485
61 M 48 NSCLC Encephalon, NOS185 72 1473 781
62 M 72 NSCLC Left frontal lobe140 nd 1277 535
63 M 55 NSCLC Left cerebellum403 235 1740 1012
64 M 71 SCLC Cerebellum122 147 1217 237
65 F 67 Breast Ca-- 80 nd 1097 634
66 F 77 Colon Ca Cerebellum121 51 1066 334
67 M 73 Kidney CaLeft frontal lobe117 103 1077 213
68 F 77 Urogenital CaLeft frontal lobe135 164 1143 125
NSCLC non-small lung carcinoma, SCLC small lung carcinoma, MMP matrix-metalloproteinase, nd n t detectable
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stainings were performed automatically with prediluted 
antibodies. Ki-67 Label Index (LI) count was performed by 
taking the average on five representative fields of neoplas-
tic cells in hot spot areas. A cut-off point to consider low 
and high Ki-67 expression was set at 4 %. An evaluation 
of percent of nuclear immunoreactivity for PR amongst the 
neoplastic cells was carried out.
Statistical analysis
All statistical analyses were performed with R statistical 
platform (vers. 3.2.3, the R Foundation for Statistical Com-
puting). Quantitative variables were described with median 
and range and compared between groups using the non para-
metric Kruskall Wallis test followed by Mann Whitney U 
test for pairwise comparisons. Correlation among variables 
were assessed using the non parametric Spearman coeffi-
cient. All statistical tests were two sided with a significance 
level set at 0.05. No correction for multiple comparisons 
was undertaken.
Results
To investigate the gelatinolytic activity present in the serum, 
substrate gel zymography was performed. This method 
allows the detection of the metalloproteinases that exhibit 
gelatinolytic activity. Representative zymography results 
are shown in Fig. 1 pa el a. Polyacrylamide gels were eval-
uated for the presence of clear zone representing degrada-
tion of gelatin by proteolysis. The nature of lytic bands was 
confirmed by inhibition assay with a selective inhibitors of 
serine proteases and with selective inhibitors of MMPs (data 
not shown). Moreover, the immunological detection of lytic 
bands has been confirmed by performing Western blotting 
with antibodies against MMP-2 and MMP-9 (Fig. 1, panel 
a, lanes 9, 10). In the sera of all patients, the gels revealed 
the existence of four clear zones representing degradation of 
gelatin by proteolysis migrating at approximately 240, 130, 
92 kDa (MMP-9) and 72 kDa (MMP-2), respectively. Com-
parison of these gelatinolytic bands with prestained standard 
protein and purified gelatinase A (MMP-2) and gelatinase B 
(MMP-9) clearly identified the MMP constituting bands as 
gelatinase A (MMP-2; 72kDa) (Fig. 1, panel a, lane 8) and 
gelatinase B (MMP-9; 92kDa) (Fig. 1, panel a lane 7). The 
clear zones with molecular weight >92kDa might represent 
complexes of MMPs that are not dissociated in zymogra-
phy. In fact, MMP-9 can be associated with a 25-kDa pro-
tein (lipocalin) giving a band at ~125kDa [17, 18] and can 
form a complex with its endogenous inhibitors TIMP-1 
giving a band at ~140 kDa [19]. Furthermore, MMP-9 can 
form dimer or multidimer giving a lytic band at approxi-
mately 240 kDa [19]. Following gelatin zymography, the 
Control gels contained either of the MMP s lective inhibi-
tors, 20 mM EDTA or 10mM 1,10 phenanthroline, in the 
MMP incubation buffer to confirm that lysis band was the 
results of MMPs. Furthermore, the character of roteolytic 
bands was analyzed by incubating t e identical zymogram  
in 0.1 mg/ml of PMSF, a serine protease inhibitor; or 2mM 
Pefabloc, an irreversible serine protease inhibitor. Follow-
ing zymography, the degree of gelatin digestion was quanti-
fied as previously described [16]. Briefly, we used an image 
analysis software (ImageQuant TL, Amersham Bioscience, 
Chicago, IL, USA) according to the m nufacturer’s sp ci-
fications. The image of the gel was inverted to reveal dark 
bands on a white background. The molecular weight, vol-
ume and background of each band were determined. The 
relative amounts of the different forms of ge atinases were 
expressed as the integrated density ×10−3 (volume) of all the 
pixels above the background of each band.
Immunohistochemistry
In 45 surgical resected specimens, consisting of 17 glial 
tumors and 28 meningiomas, immunohistochemical evalua-
tion with MMP-9 antibody was performed. All tissues were 
fixed in 10 % neutral formalin for 24 h at room tempera-
ture, embedded in paraffin at 55 °C and cut firstly in 4 μm 
thick sections that were stained with conventional routin  
hematoxylin and eosin stain used for iagnostic histologi-
cal examination; afterwards, additional 4 μm thick sections 
were used for immunohistochemistry. After dewaxing in 
xylene, rehydratation in alcohol decreasing scale and heat-
induced epitope retrieval in Tris EDTA buffer (pH 9), endo-
gen peroxidase block with 3 % H2O 2 followed. Sections 
were then incubated for 90 min, at ro m temperature, with 
anti MMP-9 monoclonal primary antib dy (Abcam EP 1254, 
rabbit), at 1:100 dilution. A streptavidin-h seradish peroxi-
dase detection system and subsequent chromo en reaction 
with diaminobenzidine (Dako) were applied. Counterstain-
ing was performed using Harris hematoxylin. Sections of 
tissue form gastric adenocarcinoma were used as positive 
control whereas the negative control was a section of glioma 
and one of meningioma stained with the s condary a tibody
alone. A different interpretation of MMP-9 sign l wa nec-
essary in the two groups of maligna ci s: in gliom  the 
site and the percent (0: no signal; +: <10 %; ++: 10–30 %; 
+++: >30 %) of reactivity were eva uated, while meningio-
mas that usually display a more homogeneous ce lular com-
position, only the percentage of r activity w s considered 
(0: no signal; +: <10 %; ++: 10–30 %; +++: >30 %). The 
immunostaining was evaluated separate y by three differ-
ent pathologists who ignored any clinical information and, 
in case of discordance, a second observation was ad  to 
a multi-head microscope, in der to reach agree nt. For 
meningiomas, Ki-67 (MIB1, Dako) and PR (1E2, Ventana) 
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activity between patients and healthy individuals have been 
observed.
A further objective of this study was to correlate expres-
sion of serum MMP-9 with the expression of the same 
protein in the tumor tissue (the putative source of the bio-
marker). To address this aim, glioma and meningioma tis-
sues were subjected to immunohistochemistry with MMP-9 
antibody. Among glial neoplasms, MMP-9 immunohisto-
chemical expression (Table 1) wa  absent in vessels and dif-
fusely present in glioma cells, both cytoplasmic and nuclear, 
when of grade II; in grade III gliomas the signal was weaker 
only cytoplasmic in glioma cells and almost lacking in neo-
plastic vessels, were observable; in glioblastomas (grade 
proteolytic bands were subjected to densitome ric an lysis 
and the data, normalized to an int rnal serum standard, were 
expressed as the integrated density of all p x ls of each band 
(volume ×10− 3). A summary of expre sion patterns of pro-
teinases in glioma, meningioma, and brain metastasi  speci-
mens is shown in Tables 1, 2 and3.
Considering the volume average of ach individual band, 
we observed that enzymatic c vit  of both monomeric nd 
multimeric forms of MMP-9 are significantly higher in high-
grade glioma, in low- and high-grade meningioma sampl s 
as well as in metastasis specimens compared to h althy 
individuals (p < 0.001) Fig. 1, panel b, and Table 4). No
statistically significant variations of MMP-2 proteolytical 
Fig. 1 Panel a Representative gelatin zymography of serum (lanes 
1–6), purified gelatinases, and Western blotting. Molecular weight 
are shown on the left. Lane 1 althy subject, lane 2 glioblastoma 
multiforme (patient 11); lane 3 oligodendroglioma (patient 5), ane 4 
intracranial metastasis from melanoma (patient 57), lane 5 l w-grade 
meningioma (patient 25), lane 6 high-grade meningioma (patient 43), 
lane 7 purified gelatinase B (MMP-9, 92 kDa) 20 µU, lane 8 purified 
gelatinase A (MMP-2, 72 kDa) 120 mU, lane 9 Western blotting of 
MMP-9 (92 kDa); lane 10: Western blotting of MMP-2 (72 kDa). Panel
bBox plot showing the distribution of multimeric form (240 kDa) and 
monomeric form (92 kDa) of serum MMP-9 in healthy controls, low-
grade meningioma (grade I), high-grade meningioma (grade II), high-
grade glioma (GB) and intracranial metastases. Value of integrated 
density are expressed as volume ×10−3. Data are shown as median 
(horizontal line in the box), Q1 and Q3 (border of the box) and min 
and max (whiskers out ide the box). Dot r present outliers values (i.e., 
data points below Q1 −1.5 × IQR r above Q3 +1.5 × I R). Q1 = 25th 
percentile; Q3 = 75th percentile; IQR (interquartile range) = Q3–
Q1. Panel c Immunohistochemestry against MMP-9 in gliomas; (a) 
grade II glioma (oligodendroglioma): diffuse cytoplasmic and nuclear 
immunoreactivity in neoplastic cells (400× mag ification); (b) grade 
III glioma (anaplastic oligodendroglioma): strong cytoplasmic signal 
nside tumor cells (400× magnification); (c) grade IV glioma (glioblas-
toma): heavy immunoreactivity in neoplastic endothelial cells lying at 
the interface of tumor-cerebral parenchyma (200× magnification); (d) 
grade IV glioma (glioblastoma): deep immunoreactivity in neoplastic 
vessel endothelial cells and occasional cytoplasmic signal within the 
tumor (400× magnificati n). Panel d Immunohistochemestry against 
MMP-9 in meningiomas (400× magnification) an  box plot s owing 
MMP-9 s ining percentage  low- and high-grade meningiomas. (a) 
gr de I meningioma: cytoplasmic immunoreaction in less than 10 % of 
neoplastic cells (b) grade II meningioma: cytoplasmic immunoreaction 
in 10–30 % of n oplastic cells (c) grade II meningioma: cytoplasmic 
immunoreaction in more than 30 % of neoplastic cells
 
1 3
J Neurooncol (2017) 131:223–232 229
role in intracranial tumors. In this preliminary study, we 
measured gelatinolytic levels of serum forms of MMPs by 
zymography, and tissue expression of MMP-9 by immuno-
histochemistry. The zymographic tests have some advan-
tages over immunological assay such as lower cost, a more 
rapid time of execution and possibility of simultaneously 
detecting multiple forms of the same enzyme. Our results 
showed that MMP-9 (92 and 240 kDa) is significantly 
increased in the sera from patients with CNS tumors com-
pared to healthy individuals and differences in MMP-9 tis-
sue expression have been underlined between glioblastoma 
and low-grade glioma specimens. Nevertheless, no relevant 
differences of MMP-9 lytic activities have been observed 
between low-grade and high-grade specimens. By immuno-
enzyme method (ELISA), Hormigo et al. observed that the 
levels of MMP-9 were higher in the sera samples of patients 
with high-grade glioma after surgery, while the MMP-9 con-
centrations were significantly lower in glioblastoma patients 
with no radiographic evidence of disease in comparison 
to the subjects with active tumor [23]. Anyway, MMP-9 
increases following brain surgery, suggesting that increases 
in the serum level of this protein may be associated with 
brain inflammation and breakdown of blood brain barrier 
rather than be a true measure of tumor burden [23]. Vice 
versa, Iwamoto e  al., in a larger cohort of glioma patients, 
observed no statistically significant association between 
levels of serum MMP-9 and radiographic disease status in 
both low- and high-grade glioma as well as between differ-
ent type of CNS tumors [24]. On the contrary, immunohisto-
chemical detection of MMP-9 in neoplastic tissues revealed 
a significantly different protein localization and distribution 
between low- and high-grade specimens. The most evident 
findings was, indeed, the de-localization of the MMP-9 sig-
nal from glioma cells (nucleus and cytoplasm) to endothelial 
cells of neoplastic blood vessels, which is directly related 
to tumor malignancy. Consistently, previous immunohisto-
chemical and in situhybridization studies had demonstrated 
that, in high-grade glioma, MMP-9 expression is mainly 
confined to perivascular regions at the infiltrating borders 
of the tumor and, in most of cases, to endothelial cells, with 
an intimate association with tumor malignant behavior [25, 
26]. These observations may suggest differential regulation 
IV), instead, a strong reactivity was detected in neoplastic 
vesels in comparison with gliomatous cells tha  wer  almost 
completely silent. Two cases of pylocitic astrocytoma and 
a ganglioglioma (grade I) did not r veal any signal (Fig.1 
panel c, and Table1). In particular, we ob er d a str ng 
positivity in 6 out 8 samples (75%) in neoplastic vessels of 
glioblastoma tissue specimens and a difference compared 
with lower grade glioma specimens (p = 0.002); how v r 
because of the small number of s mples this difference may 
be not statistically significant. Moreover, we identified an 
inverse correlation between MMP-9 tissue expression in th  
endothelial cells of neoplastic vessels and serum multimeric 
MMP-9 gelatinolytic activity (240 kDa band) with a Sp r-
man Rho of r =−0.683 and p = 0.062 values. As i  co cerns 
meningiomas, the staining r veal d: (a) mainly cytoplasmic 
MMP-9 reactivity and a strong signal in atypical m nin-
giomas compared with low-grade ones (p = 0.036) (Fi . 1, 
panel d, and Table2); (b) Ki-67 index was more xpress d
in grade II meningioma compared with grade I specimens 
(p < 0.001), whereas progesterone receptor (PR) did ot 
correlated with the tumor grading (p = 0.257). Finally, we 
found a positive correlatio  between MMP-9 and Ki-67 
with a Sperman Rho of r = 0.418 and p =0.034 values.
Discussion
Since most symptoms associated with primary and/or sec-
ondary brain tumors are also common to other diseases, the 
decision whether -or not- to investiga  for a possible tumor 
is difficult. In fact, neuro-imaging techniques (the gold 
standard methods in evaluation for brain tumors) are rela-
tively expensive and may ide tify innocen  lesion . More-
over, diagnosis must be confirmed with histopathological 
examination of tissue sampl s [20]. Thus, there is a great 
interest in identifying reliable blood biomarkers that could 
support the management of brain tumors, e.g. facili at ng 
neuro-radiological differential diagnosis at initial pres nta-
tion, planning of surgical intervention  and/or monitoring 
of the disease course [21, 22]. The ole of MMPs has been 
studied extensively in number tumors of diverse origins, 
however, to our best knowledge little is known about their 
Table 4 M dian values and range of MMP-2 and the three MMP-9 forms gelatinolytic activities in sera from glioma, meningioma and intracranial 
metastasis patients
MMP-9 (240 kDa) MMP-9 (130 kDa) MMP-9 (92 kDa) MMP-2 (72 kDa)
Healthy controls51.7 [27; 112.5] 61.4 [48.8; 90.4] 762.6 [248.7; 1274.8] 438.9 [201.9; 1117.6]
High grade gliomas111.2 [47; 342.5]* 98.8 [38.4; 213.8]1129.9 [470.2; 1684.2]*459.6 [69.8; 1025.7]
Low grade meningiomas91.5 [48.6; 232.9]*120.2 [51.6; 247.2]1038.9 [436.6; 1493.9]*490.3 [195.8; 1205.4]
High grade meningiomas113.7 [32.8; 222.6]*106 [45.6; 137.7]1185.9 [550.8; 1562.6]*617.8 [324.4; 794.4]
Intracranial metastasis154.7 [79.6; 403.1]*146.8 [45.2; 719.1]1224.9 [556.2; 2039.7]*501.9 [125.1; 1228.4]
*Significantly different from controls (p < 0.01)
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